Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | Bioventus CFO sells over $29k in company stock | 1 | Investing.com | ||
20.03. | Bioventus executive sells over $6,600 in company stock | 1 | Investing.com | ||
20.03. | Bioventus exec sells over $17k in company stock | 1 | Investing.com | ||
20.03. | Bioventus Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
13.03. | Bioventus shares target raised to $9 on solid Q4 performance | 1 | Investing.com | ||
13.03. | Earnings call: Bioventus Inc. reports solid Q4 growth, optimistic 2024 outlook | 1 | Investing.com | ||
12.03. | Bioventus Reports Upbeat Earnings, Joins Ranpak, Beachbody And Other Big Stocks Moving Higher On Tuesday | 1 | Benzinga.com | ||
12.03. | Bioventus Inc reports results for the quarter ended in December - Earnings Summary | - | Reuters | ||
12.03. | Bioventus Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
12.03. | Bioventus Inc. - 8-K, Current Report | 1 | SEC Filings | ||
12.03. | Bioventus Non-GAAP EPS of $0.07 beats by $0.05, revenue of $135.42M beats by $11.46M | 1 | Seeking Alpha | ||
12.03. | Bioventus, Inc.: Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results | - | GlobeNewswire (USA) | ||
11.03. | A Preview Of Bioventus' Earnings | 1 | Benzinga.com | ||
18.01. | Bioventus, Inc.: Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility | 240 | GlobeNewswire (Europe) | DURHAM, N.C., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it has entered... ► Artikel lesen | |
12.01. | Bioventus Inc. - 8-K, Current Report | 2 | SEC Filings | ||
12.01. | Bioventus, Inc.: Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole | 4 | GlobeNewswire (USA) | ||
09.01. | Bioventus Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
21.12.23 | Bioventus Inc. - 8-K, Current Report | 1 | SEC Filings | ||
20.12.23 | Bioventus names Medtronic, J&J veteran as CEO | 15 | MassDevice | ||
19.12.23 | Bioventus appoints Robert Claypoole as president and CEO | 1 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EPIGENOMICS | 1,790 | -1,38 % | EQS-News: Epigenomics AG veröffentlicht Finanzergebnisse für das Geschäftsjahr 2023 | EQS-News: Epigenomics AG
/ Schlagwort(e): Jahresergebnis/Jahresbericht
Epigenomics AG veröffentlicht Finanzergebnisse für das Geschäftsjahr 2023
14.03.2024 / 08:00 CET/CEST
Für... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 1,140 | -2,15 % | Raus aus BioNTech und rein in Defence Therapeutics und Evotec Aktie? | Bei der BioNTech-Aktie ist derzeit die Luft raus. Obwohl sich die Stimmung im Sektor verbessert, so ist Star-Investorin Cathie Wood kürzlich bei Moderna eingestiegen, kommt der deutsche Biotech-Primus... ► Artikel lesen | |
GINKGO BIOWORKS | 1,180 | +6,79 % | AQUA Cultured Foods Partners with Ginkgo Bioworks to Optimize Alt-Seafood Production | ||
BEAM THERAPEUTICS | 33,760 | -0,47 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
ONCOLYTICS BIOTECH | 0,940 | 0,00 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights | Pelareorep advancing to a registration-enabling study in 2024 in pancreatic cancer and expands pancreatic potential with new GOBLET cohort in combination with mFOLFIRINOX
Impressive objective response... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 10,075 | -1,61 % | Recursion Pharmaceuticals: Recursion Publishes Annual Environmental, Social and Governance Report | ||
ARCTURUS THERAPEUTICS | 32,130 | -2,13 % | Arcturus COO sells shares worth nearly $300k | ||
ASSERTIO | 0,983 | -1,75 % | Assertio Holdings, Inc. - 8-K, Current Report | ||
SIGA TECHNOLOGIES | 8,610 | +2,14 % | Dividendenbekanntmachungen (25.03.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABB LTD CH0012221716 0,999 USD 0,9242 EUR ABB LTD ADR US0003752047 0,9993 USD 0,9245 EUR ACADEMY SPORTS AND OUTDOORS INC US00402L1070 0... ► Artikel lesen | |
MERRIMACK PHARMACEUTICALS | 14,800 | +0,30 % | MERRIMACK PHARMACEUTICALS INC - 8-K, Current Report | ||
VIR BIOTECHNOLOGY | 10,090 | -0,88 % | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
"Vir... ► Artikel lesen | |
VERVE THERAPEUTICS | 13,190 | +1,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
BIO-PATH | 4,030 | -1,95 % | BIO-PATH HOLDINGS INC - 8-K, Current Report | ||
ARS PHARMACEUTICALS | 11,170 | +13,23 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results | Preparing to submit response to the FDA's CRL for neffy® (epinephrine nasal spray) in Type I allergic reactions in early Q2 2024, following successful completion of neffy repeat dose nasal allergen... ► Artikel lesen | |
ARVINAS | 41,140 | -0,87 % | Arvinas Inc.: Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer | NEW HAVEN, Conn., March 18, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen |